| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we have developed novel monoclonal antibodies (mAbs) against HBZ, and established novel ELISA system that allow the quantitative analysis of HBZ protein. Using this newly developed ELISA, we successfully detect and quantified the HBZ protein in HTLV-1 infected T cell lines as well as ATL cells from patients. Meanwhile, we have established a simple humanized mouse model of HTLV-1 infection for evaluating prophylactic and therapeutic interventions. Using this model, we found that neutralizing mAbs specific to HTLV-1 Env gp46 as well as human IgG isolated from HAM patients completely blocked the HTLV-1 infection in vivo, indicating that the neutralizing function of the antibody is essential for preventing the in vivo transmission of HTLV-1.
|
